Fischer Medical Ventures Ltd (FISCHER) AI Stock Analysis

Fischer Medical Ventures Ltd

(NSE:FISCHER)

Select Model

Rating:52Neutral

Price Target:INR 27.00▲(9.49% Upside)

Action:reiterated

Date:10/27/26

The overall score of 52 reflects a high-risk profile. The primary concern is the extremely weak cash flow, which contradicts the strong reported earnings and raises liquidity concerns. This is compounded by a bearish technical trend with the stock trading below all major moving averages and negative momentum. The high P/E ratio further adds to the downside risk, as the premium valuation is not supported by cash generation. The strong income statement and solid balance sheet provide some support, but are overshadowed by the cash flow and market headwinds.

Positive Factors

Revenue GrowthThe sharp FY2026 revenue increase demonstrates a substantial expansion in reported business scale. If the higher level is sustained, it can improve operating leverage, support investment in the company’s medical focus, and provide a stronger base for future earnings generation.

Negative Factors

Persistent Cash BurnDeeply negative operating and free cash flow despite reported accounting profitability is a major durability concern. Continued cash burn can increase reliance on external funding, reduce financial flexibility, and make the recent earnings improvement less valuable unless cash conversion improves materially.

Fischer Medical Ventures Ltd (FISCHER) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 16.23B
Dividend Yield: 0.20%
Average Volume (3M): 70.33K
Price to Earnings (P/E): 54.1
Beta (1Y): 0.48
Revenue Growth: 195.95%
EPS Growth: 1526.86%
Country: India
Employees: 40
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Fischer Medical Ventures Ltd Business Overview & Revenue Model

Company Description

Fischer Medical Ventures Limited, established in 1993 and headquartered in Chennai, India, is a global provider of medical equipment. The company's operations encompass the manufacturing, distribution, leasing, and maintenance of a wide array of medi...

Fischer Medical Ventures Ltd Financial Statement Overview

Summary

Financial performance is mixed. The income statement is strong (score 85) with exceptional revenue growth and expanding margins, and the balance sheet is solid (score 75) with low leverage. However, the cash flow statement is very weak (score 30) with significant negative operating and free cash flow, indicating earnings are not converting to cash. The overall financial health is a balance of strong growth potential and near-term liquidity risk.

Income Statement

85Very Positive

Balance Sheet

75Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2022
Income Statement
Total Revenue	3.67B	3.09B	1.11B	209.81M	0	1.79M
Gross Profit	1.06B	949.12M	191.09M	45.27M	0	1.79M
EBITDA	525.56M	430.83M	42.41M	23.61M	-1.89M	152.00K
Net Income	298.13M	312.41M	12.08M	18.38M	-2.33M	-365.00K
Balance Sheet
Total Assets	0	6.72B	4.57B	863.22M	1.90M	3.54M
Cash, Cash Equivalents and Short-Term Investments	250.46M	250.46M	2.51B	379.46M	156.00K	358.00K
Total Debt	0	1.07B	853.72M	16.77M	3.89M	11.43M
Total Liabilities	-3.87B	2.86B	1.20B	52.07M	4.20M	6.20M
Stockholders Equity	3.87B	3.85B	3.38B	811.14M	-2.29M	-2.66M
Cash Flow
Free Cash Flow	-778.10M	-1.29B	-927.25M	-78.37M	-1.77M	-1.46M
Operating Cash Flow	-694.93M	-1.01B	-867.38M	-73.52M	-1.77M	-1.46M
Investing Cash Flow	-985.52M	-86.20M	-1.25B	-313.86M	0	1,000
Financing Cash Flow	-404.42M	167.56M	3.15B	370.57M	1.48M	1.66M

Fischer Medical Ventures Ltd Technical Analysis

Technical Analysis SentimentNegative

Last Price24.66

Price Trends

50DMA32.69Negative

100DMA35.09Negative

200DMA36.50Negative

Market Momentum

MACD-2.27Positive

RSI31.46Neutral

STOCH47.02Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FISCHER, the sentiment is Negative. The current price of 24.66 is below the 20-day moving average (MA) of 28.74, below the 50-day MA of 32.69, and below the 200-day MA of 36.50, indicating a bearish trend. The MACD of -2.27 indicates Positive momentum. The RSI at 31.46 is Neutral, neither overbought nor oversold. The STOCH value of 47.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FISCHER.

Fischer Medical Ventures Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:FISCHER against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:NURECA	68Neutral	INR 2.85B	61.98	―	―	33.66%	17.10%
IN:SAKAR	66Neutral	INR 20.74B	49.03	―	―	47.99%	117.99%
IN:KRSNAA	61Neutral	INR 16.35B	16.77	―	0.40%	10.19%	20.99%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:NGLFINE	54Neutral	INR 15.76B	27.28	―	0.07%	40.45%	174.03%
IN:TARSONS	54Neutral	INR 15.52B	139.23	―	―	10.63%	-59.63%
IN:FISCHER	52Neutral	INR 16.20B	54.14	―	0.20%	195.95%	1526.86%

* General Sector Average

Performance Comparison

IN:FISCHER and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:FISCHER	Fischer Medical Ventures Ltd	24.75	-82.29	-76.88%
IN:KRSNAA	Krsnaa Diagnostics Limited	504.10	-281.30	-35.82%
IN:NGLFINE	NGL Fine-Chem Ltd.	2551.05	1006.52	65.17%
IN:NURECA	Nureca Ltd.	298.80	41.80	16.26%
IN:SAKAR	Sakar Healthcare Ltd	944.80	572.70	153.91%
IN:TARSONS	Tarsons Products Limited	291.75	2.70	0.93%

Fischer Medical Ventures Ltd Corporate Events

Fischer Medical Ventures to Email FY26 Annual Report and Hold Virtual AGM

Sep 5, 2026

Fischer Medical Ventures Ltd has notified stock exchanges that its Annual Report for the financial year 2025–26 will be dispatched to shareholders electronically, in line with regulatory allowances for digital communication. The company also an...

Fischer Medical Ventures Plans One-to-One Virtual Meet With Institutional Investors

Sep 4, 2026

Fischer Medical Ventures Ltd has announced that it will host a one-to-one virtual meeting with institutional investors on Monday, 7 September 2026 at 12:30 p.m. IST. The session will focus on the company’s business and general information alrea...

Fischer Subsidiary TMIV Imaging Debuts AI-Driven CLARION CT System in India

Aug 28, 2026

Time Medical International Ventures (India) Private Ltd., the wholly owned subsidiary of Fischer Medical Ventures Limited, has launched its next-generation CLARION 64/128-slice AI-driven CT system in India, unveiled at the India Health Expo 2026. The...

Fischer Medical Ventures Opens SEBI-Compliant Window for Physical Share Transfer Re-Lodgement

Aug 11, 2026

Fischer Medical Ventures Ltd has announced that it has published newspaper advertisements in Financial Express and Vishalandra to inform shareholders about a SEBI-mandated special window for re-lodgement of transfer requests for physical shares. The...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026

Fischer Medical Ventures Ltd AI Stock Analysis